Curocell
Financials
Valuation Metrics
Curocell's Market Cap is ₩4142B. At end of 2025 it was ₩6845B. Ranked #547 of 2,436 in KR market (top 22%), #211 of 1,649 on KOSDAQ (top 13%), #61 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 414.18B KRW | KR#547/2,436 Sec#61/234 |
| Revenue | 0 KRW | KR#2,404/2,436 Sec#230/234 |
| Net Income | -48.20B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 100.76B KRW | KR#1,736/2,436 Sec#139/234 |
| Net Assets | 24.53B KRW | KR#2,220/2,436 Sec#204/234 |
| Employees | 126 | KR#1,452/2,436 Sec#115/234 |
| Value | ||
| P/B | 16.88x | KR#2,379/2,436 Sec#220/234 |
| FCF Yield | -7.32% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -196.50% | KR#2,373/2,436 Sec#226/234 |
| ROA | -47.84% | KR#2,351/2,436 Sec#217/234 |
| Financial Health | ||
| Debt Ratio | 310.74% | KR#2,154/2,436 Sec#221/234 |
| Total Debt | 46.41B KRW | KR#1,012/2,436 Sec#70/234 |
| FCF | -30.31B KRW | KR#2,000/2,436 Sec#193/234 |
| Cash | 4.00B KRW | KR#2,076/2,436 Sec#190/234 |
| Current Ratio | 0.36x | KR#2,309/2,436 Sec#227/234 |
| Performance | ||
| 1Y Return | -22.62% | KR#1,532/2,436 Sec#131/234 |
| 1M Return | -14.60% | KR#2,085/2,436 Sec#197/234 |
| From 52W High | -58.79% | KR#1,835/2,436 Sec#151/234 |
| 1Y MDD | -67.92% | KR#1,850/2,436 Sec#157/234 |
| Trading | ||
| Volume | 48,003 shares | KR#1,713/2,436 Sec#158/234 |
| Foreign Own. | 1.51% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -3,336 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,628 KRW | KR#2,123/2,436 Sec#183/234 |
Company Info
Qurocell was established in 2016 as a specialized enterprise for CAR-T therapeutic agent development and listed on the KOSDAQ market in 2023. The company holds several new drug pipelines, including CD19 CAR-T therapeutic agents, and completed clinical trials for Limcato, which applies OVIS™ CAR-T technology. Aiming for a 2025 product launch, it completed a manufacturing facility and applied for product approval in 2024, while also exploring expanded development for various cancer types and overseas market entry. Qurocell is headquartered in Yuseong-gu, Daejeon Metropolitan City.